In future studies, we plan to broaden the sample range to encompass early-stage diffuse large B-cell lymphoma (DLBCL) as well as other blood tumors in order to validate and establish the reliability of the 5hmC marker for early diagnosis of DLBCL patients.Finally, the regulatory mechanism of 5hmC in DENND1A is still not clear. Here, DENND1A is linked to hematopoietic and lymphoid system neoplasm.